Left Atrial Appendage Closure

Progress in Cardiovascular Diseases

Volumn 58, Issue 2, 2015, Pages 195-201

  Lin, Albert C ^a   Knight, Bradley P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Atrial fibrillation; Left atrial appendage; Left atrial appendage closure

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIAC IMPLANT; CARDIAC PLUG; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DEVICE APPROVAL; EFT ATRIAL APPENDAGE CLOSURE; HEART ATRIUM APPENDAGE; HEART SURGERY; HUMAN; RISK REDUCTION; SUTURE DELIVERY DEVICE; ADVERSE EFFECTS; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; DEVICES; EMBOLISM; HEART CATHETERIZATION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; STROKE; SURGERY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC CATHETERIZATION; CARDIAC SURGICAL PROCEDURES; EMBOLISM; HEMORRHAGE; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84942084614     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.07.009     Document Type: Article

References (41)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults; national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
2. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987, 147:1561-1564.
3. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
4. Tu H.T., Campbell B.C., Christensen S., et al. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerbrovasc Dis 2010, 30:389-395.
5. Murray C.J., Atkinson C., Bhalla K., et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013, 310:591-608.
6. Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996, 61:755-759.
7. Manning W.J., Silverman D.I., Keighley C.S., Oettgen P., Douglas P.S. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short term anti-coagulation: final results of a prospective 4.5year study. J Am Coll Cardiol 1995, 25:1354-1361.
8. Al-Saady N.M., Obel O.A., Camm A.J. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999, 82:547-554.
9. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011, 57:101-198.
10. Granger C.B., Armaganijan L.V. Should newer oral anticoagulants be used as first line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism?. Circulation 2012, 125:159-164.
11. Lin A.C., Knight B.P. Ablation for persistent atrial fibrillation pulmonary vein isolation plus what?. JACCEP 2015, 1:161-163.
12. Lakkireddy D., Mahankali A.S., Kanmanthareddy A., et al. Left atrial appendage ligation and ablation for persistent atrial fibrillation: the LAALA-AF registry. JACCEP 2015, 1:153-160.
13. Kawamura M., Scheinman M.M., Lee R.J., Badhwar N. Left atrial appendage ligation in patients with atrial fibrillation leads to a decrease in atrial dispersion. J Am Heart Assoc 2015, 14. 10.1161/JAHA.114.001581.
14. 2HAGES, ATRIA, and HAS-BLED bleeding risk prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS study. J Am Coll Cardiol 2012, 60:861-867.
15. Onalan O., Lashevsky I., Hamad A., Crystal E. Nonpharmacologic stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther 2005, 3:619-633.
16. Sudlow M., Thomson R., Thwaites B., Rodgers H., Kenny R.A. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998, 352:1167-1171.
17. Brass L.M., Kromholz H.M., Scinto J.M., Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997, 28:2382-2389.
18. Connolly S.J., Ezekowitz M.D., Yusef S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
19. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
20. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
21. Hansen M.L., Sorensen R., Clausen M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010, 170:1433-1441.
22. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for the prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 2009, 374:534-542.
23. Reddy V.Y., Doshi S.K., Sievert H., et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3year follow-up for the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 2013, 127:720-729.
24. Reddy V.Y., Holmes D.R., Doshi S.K., Neuzil P., Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011, 123:417-424.
25. Holmes D.R., Lakireddy D.R., Whitlock R.P., Waksman R., Mack M.J. Left atrial appendage occlusion opportunities and challenges. JACC 2014, 63:291-298.
26. Holmes D.R., Kar S., Price M.J., et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long term warfarin therapy; the PREVAIL trial. JACC 2014, 64:1-12.
27. Brief Summery of the Circulatory System Device Panel Meeting - October 8, 2014 Available at:. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM419373.pdf.
28. Reddy V.Y., Mobius-Winkler S., Miller M.A., et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). JACC 2013, 61:2551-2556.
29. Urena M., Rodes-Cabau J., Freixa X., et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with non-valvular atrial fibrillation and contraindications to anticoagulation therapy. JACC 2013, 62:96-102.
30. Lam S.C., Bertog S.C., Gafoor S., et al. Left atrial appendage closure using the Amulet Device-a single center experience. JACC 2013, 62:B210.
31. Bartus K., Bednarek J., Myc J., et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm 2011, 8:188-193.
32. Bartus K., Han F.T., Bednarek, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patient with atrial fibrillation: initial clinical experience. JACC 2013, 62:108-118.
33. Price M.J., Gibson D.N., Yakubov S.J., et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the US transcatheter LAA ligation consortium. JACC 2014, 64:565-572.
34. Pillarisetti J., Reddy Y.M., Gunda S., et al. Endocardial (Watchman) vs epicardial (LARIAT) left atrial appendage exclusion devices: understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm 2015, 12:1501-1507.
35. Giedrimas E., Lin A.C., Knight B.P. Left atrial thrombus after appendage closure using LARIAT. Circ Arrhythm Electrophysiol 2013, 6:e52-e53.
36. Lakkireddy D., Vallakati A., Kanmanthareddy A., et al. Left atrial thrombus formation after successful left atrial appendage ligation; case series from a nationwide survey. J Am Coll Cardiol 2015, 65(15):1595-1596.
37. Lakireddy D., Mahankali A.S., Kanmanthareddy A., et al. Left atrial appendage ligation and ablation for persistent atrial fibrillation (LAALA-AF registry). J Am Coll Cardiol EP 2015, 1:153-160.
38. Katz E.S., Tsiamtsiouris T., Applebaum R.M., Schwartzbard A., Tunick P.A., Kronzon I. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. J Am Coll Cardiol 2000, 36:468-471.
39. Ailawadi G., Gerdisch M.W., Harvey R.L., et al. Exclusion of the left atrial appendage with a novel device; early results of a multicenter trial. J Thorac Cardiovasc Surg 2011, 142:1002-1009.
40. FDA Website - Safety alerts for human medical products Available at:. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm446116.htm.
41. Coherex WAVECREST I left atrial appendage occlusion study Available at:. https://clinicaltrials.gov/ct2/show/NCT02239887.